Monday, May 18, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

How Confident Are You in RFK Jr.’s Health Leadership?

Survey: Public Confidence in RFK Jr.’s Leadership in Health Policy

Response scale for all items:
Strongly disagree · Disagree · Neither agree nor disagree · Agree · Strongly agree

RFK Jr.’s prior work as an environmental attorney is relevant and beneficial to health policy leadership roles.
I am confident in RFK Jr.’s overall ability to lead and oversee national health policy institutions.
RFK Jr.’s public criticisms of segments of the pharmaceutical industry align with my understanding of current policy and market challenges.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight reduce my confidence in his health policy judgment.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight do not reduce my confidence in his health policy judgment.
RFK Jr.’s communication style and public persona support effective collaboration with scientific and regulatory stakeholders
RFK Jr.’s communication style and public persona could make it harder to build consensus across health agencies and expert groups.
RFK Jr.’s disclosed history of substance use disorder does not affect my assessment of his present capacity for public leadership.
RFK Jr.’s disclosed history of substance use disorder raises concerns for me about suitability for senior public leadership roles.
RFK Jr.’s policy positions indicate a willingness to challenge existing regulatory and industry frameworks in ways that could improve public health outcomes.
RFK Jr.’s policy positions introduce a level of uncertainty that could increase risk in national health decision-making.
I have sufficient familiarity with RFK Jr.’s public statements and policy positions to make a confident judgment about his leadership suitability.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!